Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Inhaled Insulin To Resume Phase III Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Trials for the AERx inhaled insulin system will involve both type 1 and type 2 diabetes, despite a previous safety signal in type 1 patients.

You may also be interested in...



Novo Nordisk Seeks To Block Sale Of Exubera, Claims Patent Infringement

The insulin maker says Pfizer's Exubera infringes Novo's patents covering inhaled insulin.

Novo Nordisk Seeks To Block Sale Of Exubera, Claims Patent Infringement

The insulin maker says Pfizer's Exubera infringes Novo's patents covering inhaled insulin.

Lilly Begins Efficacy Study For Inhaled Insulin

The non-inferiority study is the third part of Lilly and Alkermes' "comprehensive" clinical program.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel